Lakefront Biotherapeutics NV files 20-F

Galapagos NV reported a net profit of €320.9 million for the fiscal year ended December 31, 2025, primarily driven by the recognition of €1,069.0 million in deferred income related to its collaboration agreement with Gilead. The company is undergoing a strategic transformation, including the wind-down of its cell therapy activities, and plans to focus on business development to acquire new product candidates.